-
- 北中 順惠
- 兵庫医科大・医・薬理
-
- 北中 純一
- 兵庫医科大・医・薬理
-
- 天津 優紀恵
- 兵庫医科大・医・薬理
-
- 大澤 礼奈
- 兵庫医科大・医・薬理
-
- 佐藤 実歩
- 兵庫医科大・医・薬理
-
- 橋本 紘卓
- 兵庫医科大・医・薬理
-
- 久富 衣璃菜
- 兵庫医科大・医・薬理
-
- 喜多尾 衣莉
- 兵庫医科大・医・薬理
-
- 三村 真梨
- 兵庫医科大・医・薬理
-
- 中村 美裕
- 兵庫医科大・医・薬理
-
- 田上 健太
- 兵庫医科大・医・薬理
-
- 田中 康一
- 兵庫医療大・薬・薬理
-
- 富田 和男
- 兵庫医療大・薬・薬理 鹿児島大・院医歯学総合・歯科応用薬理
-
- 佐藤 友昭
- 鹿児島大・院医歯学総合・歯科応用薬理
-
- 西山 信好
- 兵庫医療大・薬・薬理
-
- 竹村 基彦
- 兵庫医科大・医・薬理
書誌事項
- タイトル別名
-
- Histamine H<sub>3</sub> receptor inverse agonists attenuate methamphetamine-induced hyperlocomotion in mice via histamine H<sub>1</sub> receptors
抄録
<p>A single administration with METH induced a hyperlocomotion in mice. Pretreatment of mice with pitolisant, a histamine H3 receptor inverse agonist, for 30 min showed a significant reduction of the hyperlocomotion induced by METH, as compared with vehicle-pretreated subjects, in a dose-dependent manner. Pretreatment of mice with JNJ-10181457, another H3 receptor inverse agonist, showed a similar inhibitory effect on METH-induced hyperlocomotion. No significant change in locomotion was observed in mice pretreated with pitolisant or JNJ-10181457 alone. Pretreatment with pitolisant prior to a high-dose METH significantly decreased the intensity of stereotyped behaviors and increased its latency to onset in a dose-dependent manner. The pitolisant action on METH-induced hyperlocomotion was completely abolished by a H1 receptor antagonist pyrilamine, but not by H2 receptor antagonist zolantidine. These observations suggest that pretreatment with pitolisant attenuates METH-induced hyperlocomotion via histamine receptors subtype H1 but not H2, and support the idea that activation of brain histamine systems may be a good strategy for the development of agents which treat METH abuse.</p>
収録刊行物
-
- 日本薬理学会年会要旨集
-
日本薬理学会年会要旨集 92 (0), 3-P-049-, 2019
公益社団法人 日本薬理学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390283659861304448
-
- NII論文ID
- 130007813315
-
- ISSN
- 24354953
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可